ArticlePoultry science2026
Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative APTM against Mycoplasma gallisepticum.
Article in Poultry science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma gallisepticum (MG) is a primary avian pathogen that causes chronic respiratory disease, leading to significant economic losses in the poultry industry. This study aimed to investigate the pharmacokinetic/pharmacodynamic (PK/PD) relationship of a novel pleuromutilin derivative, 14-O-[(4-amino-6-hydroxy-pyrimidine-2-yl) thioacetyl] mutilin (APTM), against MG in a chicken infection model to provide a basis for a rational dosage regimen. The in vitro activity of APTM against MG strain S6 was assessed by determining the minimum inhibitory concentration (MIC) and time-kill kinetics. An intratracheal MG infection model was established in chickens. The pharmacokinetic profile was evaluated after single oral administrations of APTM at 5, 15, and 40 mg/kg. The pharmacodynamic efficacy was determined by quantifying the bacterial reduction in the lungs after three consecutive days of oral treatment with doses ranging from 0 to 40 mg/kg. The PK/PD data were integrated and analyzed using an inhibitory sigmoid Emax model. The MIC of APTM against MG S6 was 0.03125 µg/mL, and in vitro time-kill assays demonstrated concentration-dependent bactericidal activity. In chickens, APTM was rapidly absorbed (T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.